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SHORT COMMUNICATION
Towards quality control in cancer chemotherapy
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Summary A survey of all hospital pharmacies in the former North Western Regional Health Authority has
revealed that hospital personnel continue to prepare cytotoxic drugs in suboptimal conditions, despite the
widespread introduction of pharmacy cytotoxic reconstitution services. Other concerns include the lack of
formal training for medical staff in the administration of these agents and the frequent absence of written
procedures for dealing with extravasation and chemotherapy errors.
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A series of well-publicised accidents in which patients have
died as a result of errors in the administration of cytotoxic
agents (Sunday Times, 1993; Zaragoza et al., 1995) are a
reminder that these drugs remain among the most toxic
substances commonly administered.
Occupational exposure to cytotoxic drugs has been
associated with adverse pregnancy outcomes (Hemminki et
al., 1985; Selevan et al., 1985; McDonald et al., 1988; Stucker
et al., 1990), an excess risk of leukaemia (Skov et al., 1990,
1992) and case reports of bladder (Levin et al., 1993) and
nasopharyngeal carcinoma (Gabriele et al., 1993). An Aust-
ralian pharmacist recently won industrial compensation when
he presented with duodenal cancer after preparing cytotoxic
drugs in a faulty biohazard cabinet that had repeatedly failed
safety checks (Hudson, 1990; Carden, 1991; Rodriguez and
Yap, 1991).
Although the absence of robust measures of exposure and
the need to ascertain rare outcome events make it difficult to
precisely quantify the risk to healthcare personnel, most
countries have introduced formal guidelines (Health and
Safety Executive, 1983; Pharmaceutical Society Working
Party, 1983; OSHA, 1986; Skov, 1993) that aim to reduce
staff exposure to antineoplastic drugs to the lowest prac-
ticable level. The Joint Council for Clinical Oncology (JCCO)
has also recently published a series of recommendations that
clarify the responsibilities of medical staff for the prescribing
and administration of cancer chemotherapy (Table I) (JCCO,
1994).
We now report a regional survey, the aim of which was to
describe the delivery of cancer chemotherapy before the
dissemination of the JCCO guidelines (JCCO, 1994). Our
objectives were to report on current practices relating to the
prescribing, preparation and administration of cancer
chemotherapy.
Method
A postal questionnaire, prepared and piloted in consultation
with medical oncologists and hospital pharmacists, was dist-
ributed to all hospital pharmacies in the former North
Western Regional Health Authority in July 1993. Construc-
tion of the questionnaire was informed by a draft of the
JCCO (1994) guidelines and previous published guidelines
(Health and Safety Executive, 1983; Pharmaceutical Society
Working Party, 1983) relating to the safe handling of cancer
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chemotherapeutic agents. All responded but as not all ques-
tions were always answered the denominator used when
reporting responses varies slightly. Results were circulated to
all participating pharmacists and discussed at workshops
attended by pharmacists and medical oncologists.
Results
Cancer chemotherapeutic agents were prescribed in 29 (64%)
of the 45 hospitals within the Region. Only one unit had
guidelines relating to the grade of medical staff authorised to
write prescriptions. When checking prescriptions 23 (82%)
pharmacists routinely sought additional information on
patients' weight, height and surface area. A summary of
patients' drug history was held in pharmacy in 13 (48%)
units. Twenty-three pharmacists (82%) also routinely con-
sulted relevant clinical protocols, but three (11%) did not
seek any additional information to that provided on the
prescription form.
Pharmacy cytotoxic reconstitution services were available
on site in 21 of the 29 units (72%). Of the eight hospitals
with no on-site facility, the services of an outside hospital
were used in four and drug preparation took place on the
ward or outpatient department in the remainder. Even where
pharmacy reconstitution services were provided on site,
Table I Summary of JCCO recommendations
Cancer chemotherapy should be carried out in designated, properly
equipped areas
Cancer chemotherapy should only be carried out by experienced
trained staff
Cytotoxic drug regimens should only be initiated by consultants,
senior registrars and associate specialists with appropriate training
Registrars and SHOs who administer cytotoxic drugs must seek
advice if a change of drug dosage become necessary
Cancer chemotherapy trial protocols must be available on the ward,
in the clinic and in pharmacy








Responsibility for the maintenance of safe procedures and standards
of practice lies with the consultant concerned
Cancer chemotherapy should be undertaken within the normal
working hours wherever possibleQuality control in cancerchemotherapy
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cytotoxic drugs were also prepared on the ward, day ward or
outpatient department in 19 units. An isolator or vertical
laminar air flow cabinet was available in all pharmacies, but
in only two (11%) of the clinical areas where drugs were
prepared. Written instructions on drug preparation were
always available in pharmacy but at other locations in only
seven hospitals.
Only five units had chemotherapy nurses and in 26 i.v.
bolus injections were routinely administered by medical staff.
All chemotherapy nurses had received formal training in the
administration of cytotoxic drugs, but in only one unit was
this available for medical staff. Written instructions were
available for the management of extravasation in 23 (88%)
units but an extravasation kit was located in treatment areas
in only 13 (48%); in only three were there written procedures
for dealing with chemotherapy errors.
Discussion
The results of this survey have implications for clinicians,
pharmacists and hospital managers.
The most contentious issue relates to the grade of medical
staff authorised to write prescriptions. Although it is difficult
to be prescriptive when experience and the level of super-
vision may vary within career grade and across institutions, it
is not unreasonable to suggest that the initial prescription for
each patient or any substantial modification to the
chemotherapeutic regimen should be signed by a consultant
or senior registrar. Although the increasing number of
chemotherapy nurses is welcomed, it seems inevitable that
medical staff will continue to administer chemotherapeutic
agents, particularly in smaller units. These staff receive little
or no formal training in the administration and safe handling
of cytotoxics.
This survey suggests that some aspects of good pharmacy
practice need reinforcing. All prescriptions should be checked
against the chemotherapy protocol and, in order to do this,
pharmacists should have details of a patient's height, weight
and surface area. This process would be facilitated if pro-
tocols were held in pharmacy. Ideally, pharmacy reconstitu-
tion services should be the sole agency preparing cytotoxic
drugs but despite the widespread introduction of these ser-
vices there may be a continuing need in emergencies for the
preparation of agents outside pharmacy. It is a matter for
concern that hospital personnel are still preparing cytotoxic
drugs under suboptimal conditions. Those involved with risk
management should also be concerned at the frequent
absence of written guidelines relating to the management of
extravasation and procedures for the systematic recording of
substantial errors or accidents that occur in the prescription,
preparation and administration of these agents.
The recent JCCO (1994) recommendations provide a very
necessary stimulus towards improving the delivery of cancer
chemotherapy, but responsibility for ensuring these are trans-
lated into safe operational procedures and standards of prac-
tice lie with medical, nursing and pharmacy staff. The clinical
audit process provides the means and the opportunity to
ensure that good practice is maintained.
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